PB2319: ZUMA-23: A GLOBAL, PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD OF CARE AS FIRST-LINE THERAPY IN PATIENTS WITH HIGH-RISK LARGE B-CELL LYMPHOMA

Detalles Bibliográficos
Autores principales: Westin, Jason, Jacobson, Caron, Chavez, Julio C, Sureda, Anna, Morschhauser, Franck, Glass, Bertram, Dickinson, Michael, Davies, Andrew J., Flinn, Ian W., Maloney, David, Chamuleau, Martine, Tees, Michael, Xue, Allen, Shahani, Shilpa, Nikolajeva, Olga, Kang, Janet, Kaplan, Aida, Schupp, Marco, Miao, Harry, Rich, Elizabeth Shima
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Publication Only
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429721/
http://dx.doi.org/10.1097/01.HS9.0000975996.32786.92

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429721/
http://dx.doi.org/10.1097/01.HS9.0000975996.32786.92

Ejemplares similares